Randomized trial assesses mavoglurant’s impact on motor fluctuations in Parkinson’s disease, indicating modest effects.
To assess the efficacy of mavoglurant, a metabotropic glutamate receptor 5 (mGluR5) antagonist, on motor fluctuations and dyskinesia in Parkinson’s disease (PD).
No takes yet. Share an insight, caveat, or question.
Abidin et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: